ANTECH
23.4.2024 08:01:29 CEST | Business Wire | Press release
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.”
Nu.Q® Canine Cancer Test is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers. Nu.Q® testing, run on the Element i+ analyser, is both cost-effective and simple, requiring only 50µL of EDTA plasma from a patient and providing accurate results in 5 to 10 minutes. Studies2 have shown >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q®. As the only patient-side in-house test that provides rapid and accurate results from EDTA plasma, the Nu.Q® test is an aid to diagnosis that can be run in clinic by veterinary professionals during annual check-ups or regular senior wellness exams.
Dr. Maximiljan W. Krauss, Dipl. ECVS, Tierklink Düsseldorf, used Nu.Q® Canine Cancer Test first-hand during the pilot phase and commented: “At our clinic, we see around 1500 cases of cancer in dogs a year. Lymphoma and hemangiosarcoma are the most common type of cancer we see affecting dogs as young as five years old. Thanks to Nu.Q® Canine Cancer Test and the Element i+ in-house analyzer, we have a fast and accurate means to screen for cancer, which helps us intervene early and choose the best possible care pathway for every patient. At the end of the day, early interventions can make a real difference to a dog’s quality of life and the time they have to spend with their family.”
Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied under license by Belgian Volition SRL.
Nu.Q® will be available in the UK as part of the European launch. For orders and more information about the product, please contact Antech UK.
About Mars Science & Diagnostics and Antech
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business, Antech, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90+ reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel™ DNA test products, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
2 Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422725707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi’s Decision Intelligence Summit Comes to Prague13.10.2026 09:00:00 CEST | Press release
The Gurobi Summit EMEA returns October 13–14 to showcase why optimization is the AI that drives trusted decisions. Gurobi Optimization, LLC, the leader in decision intelligence technology, today unveiled the 2026 Gurobi Decision Intelligence Summit (“Gurobi Summit”) EMEA, taking place October 13–14 in Prague. Following the U.S. version of the event, which took place September 22-23 in Las Vegas, attendees in the EMEA region will gather at the Fantova Budova for two days of innovative use case presentations, in-depth trainings, and expert-led panels. Sessions will highlight how optimization is the most suitable form of AI for delivering actionable, defensible decisions, and how generative AI can break down barriers to entry and help more users apply optimization’s full potential. This year’s presentations will include speakers from ALDI, Dutch Railways, Ryanair Labs, SAP, Skydance, and more. Several of Gurobi’s partners will also be present to showcase their solutions and expertise. In
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 09:00:00 CEST | Press release
Authorisation covers custody, exchange of crypto-assets for funds and for other crypto-assets, execution of orders and transfer services YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member Sta
Manhattan Wins Kesko Mandate as Nordic Retail Giant Bets on Cloud-Native, AI-Driven Warehousing13.10.2026 09:00:00 CEST | Press release
The race to modernise Europe's grocery supply chains has entered a new phase, with Finnish retail group Kesko selecting ActiveWarehouse™ from leading supply chain and omnichannel commerce solutions provider Manhattan Associates Inc. (NASDAQ: MANH). The Nordic retail giant is replacing its grocery trade legacy warehouse management system with the industry’s leading, cloud-native warehouse management solution, including agentic AI capabilities delivered through ActiveAgents™ and Agent Foundry. For Finland’s second largest grocery brand, and one of the biggest in Northern Europe, the investment reflects the growing strategic importance of operational agility, as digital and physical retail become increasingly interconnected and a broader shift taking place across retail logistics more generally. The scale of Kesko’s grocery trade makes the project noteworthy in Finnish and European retail. In 2025, the division’s net sales amounted to EUR 6.5 billion, and its comparable operating profit w
Horizon3 Promotes Keith Poyser to General Manager, EMEA Following More Than 260% Regional Revenue Growth13.10.2026 09:00:00 CEST | Press release
Poyser built the EMEA team from eight to more than 110 employees and will lead the company’s next phase of expansion across the region. Horizon3 today announced the promotion of Keith Poyser to General Manager, EMEA. Previously Vice President, EMEA, Poyser will oversee the company’s next phase of growth and expansion across Europe, the Middle East and Africa. His promotion follows more than 260% regional revenue growth in the last fiscal year and the opening of Horizon3’s EMEA headquarters in Amsterdam. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013365926/en/ Keith Poyser promoted to General Manager, EMEA following more than 260% regional revenue growth Since joining Horizon3 in September 2024, Poyser has recruited experienced talent and established a regional leadership bench, growing the EMEA team from eight to more than 110 employees. He has built a culture of trust, collaboration and accountability to support the
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing13.10.2026 07:00:00 CEST | Press release
New clinical data identify optimized injectable aesthetics treatment protocol for menopause-induced skin changes 56% of women have experienced ‘The Menopausal Skin Misread’, admitting they first put menopause-related skin changes down to ageing, while fewer than a third (29%) recognized menopause as the cause1 A significant knowledge gap remains: one in two women are unaware that hormonal changes during perimenopause and menopause can affect the skin, and 82% agree that better understanding the difference between menopause-related skin changes and general ageing would help them feel more informed and in control of their skincare decisions1 New data from an investigator-initiated trial (IIT) led by Dr. Andreas Nikolis and supported by Galderma, demonstrated that a sequenced treatment approach using Restylane Skinboosters followed by Sculptra delivered significant improvements in skin hydration and remodeling across the face and décolletage in menopausal women, highlighting the value of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom